PAX5 aberrant expression incorporated in MIPI-SP risk scoring system exhibits additive value in mantle cell lymphoma - Journal of Molecular Medicine
Source : https://link.springer.com/article/10.1007/s00109-023-02313-8
Abstract Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin lymphoma with highly heterogeneous clinical courses. Paired-box 5 (PAX5), the regulator of B cell differentiation and growth, is abnormally expressed in several types of cancers. Herein, we explored the prognostic value of PAX5 in MCL by comprehensively analyzing the clinical features and laboratory data of 82 MCL cases.
Conclusions/Relevance: This study provides insight into the potential role of PAX5 in MCL, and the novel risk scoring system MIPI-SP optimizes the risk stratification and facilitates prognosis evaluation in MCL patients.
• Source: Journal of Molecular Medicine
• Conclusions/Relevance: “This study provides insight into the potential role of PAX5 in MCL, and the novel risk scoring system MIPI-SP optimizes the risk stratification and facilitates prognosis evaluation in MCL patients …. The MIPI-SP risk scoring system was established and exhibited a superior prognostic value for OS depending on an area under the curve (AUC) of (95% CI, 0.658–0.881) than MIPI score …. Bioinformatic analysis of PAX5-related genes supported the mechanistic roles of PAX5 in MCL.”
• Paired-box 5 (PAX5) mediates B cell differentiation and growth and is abnormally expressed in different cancers. In the current study, researchers assessed the prognostic value of PAX5 in MCL via comprehensive analysis of the clinical features and laboratory data of 82 MCL cases.
• PAX5 positivity was correlated with shorter overall survival (OS; P = 0.011) and was an independent prognostic indicator in MCL patients. Elevated β2-MG (P = 0.027) and advanced Mantle Cell Lymphoma International Prognostic Index (MIPI) score (p = 0.014) correlated with positive PAX5 expression.
• “MIPI-SP risk scoring system has superior prognostic value than MIPI score in MCL,” per the authors.